



COVID Vaccines: Design, Development, and Immune Response Studies

Guest Editors:

Prof. Dr. Fabrizio Maggi

Department of Medicine and
Surgery, University of Insubria,
21100 Varese, Italy

Dr. Licia Bordi

Laboratory of Virology, National
Institute for Infectious Diseases
"L. Spallanzani", Via Portuense
292, 00149 Rome, Italy

Deadline for manuscript
submissions:

31 May 2024

Message from the Guest Editors

COVID-19 vaccines have represented an unprecedented effort to contain a pandemic. Developed at record time, they have saved millions of lives over the past couple of years. Nevertheless, there is still room for improvement at different fronts, ranging from the elicitation of mucosal immunity and the prevention of transmission to the ability to elicit greater immune responses in immunocompromised patients. While it is currently not clear whether yearly boosts will continue to be required, multivalent vaccines based on updated versions of the Spike protein are under development, as well as vaccines based on SARS-CoV-2 antigens other than Spike, and combo vaccines with flu and pneumococcus. In this Special Issues, we welcome original research and systematic reviews on vaccine design, immune responses, and different boosting protocols.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

Contact Us

Vaccines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com